Silence Therapeutics (SLNCF) Stock Price, News & Analysis

Company Overview

Silence Therapeutics plc is a clinical‐stage biopharmaceutical company dedicated to developing small interfering RNA (siRNA) therapeutics that silence disease‐causing genes. Utilizing its proprietary mRNAi GOLD™ platform, the company engineers lipid‐based nanoparticles for the targeted delivery of siRNA molecules to specific tissues. By harnessing the precision of RNA interference, Silence aims to address a range of diseases, including rare genetic disorders and cardiovascular conditions, where conventional therapies have shown limited efficacy.

The company’s lead pipeline candidates include SLN124, an investigational siRNA therapy designed to regulate iron metabolism in patients with iron overload disorders, and SLN360, which targets elevated lipoprotein(a) levels to reduce cardiovascular risk. Both programs have advanced through preclinical stages, with SLN124 entering clinical trials. In addition to these core assets, Silence is exploring next‐generation delivery approaches and expanding its research portfolio to encompass oncology and other areas of high unmet medical need.

Founded in 1998 and headquartered in London, Silence Therapeutics maintains research and development operations in the United Kingdom, the United States, and continental Europe. The company’s global footprint supports collaboration with academic institutions and strategic partners, enabling access to complementary expertise and resources. Silence has entered partnerships with leading pharmaceutical companies to co‐develop and commercialize select pipeline assets, accelerating the translation of its siRNA platform into potential therapies.

Under the leadership of Chief Executive Officer Christian Wojtulewicz, Silence Therapeutics continues to build its pipeline and refine its delivery technologies. Guided by a commitment to innovation and patient impact, the company seeks to advance its siRNA candidates through clinical development and ultimately deliver transformative treatments for conditions driven by aberrant gene expression.

Key Stats

• Today's Range: $1.60 to $1.60
• 50-Day Range: $0.97 to $1.65
• 52-Week Range: $0.50 to $14.75
• Volume: N/A
• Average Volume: 13,730 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

SLNCF Stock Analysis - Frequently Asked Questions

How have SLNCF shares performed this year?

Silence Therapeutics' stock was trading at $2.6250 at the beginning of 2025. Since then, SLNCF stock has decreased by 39.0% and is now trading at $1.60.

How do I buy shares of Silence Therapeutics?

Shares of SLNCF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 7/17/2025
• Next Earnings (Estimated): 8/15/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:SLNCF
• CIK: 1479615
• Web: www.silence-therapeutics.com
• Phone: 442034576900
• Fax: N/A
• Employees: 100
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A